Tibet Region Tries Moving People Away From Endemic Bone Disease
This article was originally published in PharmAsia News
Executive SummaryThe Tibet region of China reports 170,000 people at risk for the rare Kaschin-Beck bone disease, which is rare and lacks a cure
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.